Quick Take: ESMO 2026 LBA title release - Kelun and Hansoh to report on global trials in addition to China Ph3s

ESMO LBA titles were released today - content to be revealed on the days of presentations (23-27 Oct 2026). Kelun-Biotech: OptiTROP-Lung06 is the most important readout, testing sac-TMT plus pembrolizumab versus chemo plus pembrolizumab in the large 1L PD-L1-negative non-squamous NSCLC setting; TroFuse-005 is the first global Ph3 validation of efficacy previously shown by China-only trials, although the commercial opportunity is smaller given the later-line endometrial cancer setting. Hansoh: two ADC readouts further broaden the clinical landscape - HS-20093 (B7-H3 ADC) will report China Ph3 in osteosarcoma, broadening the asset's landscape following the positive 2L SCLC Ph3 readout at WCLC 2026, while B7-H4 ADC HS-20089/GSK5733584 will feature global BEHOLD-1 data in PROC. Innovent: IBI343 (CLDN18.2 ADC) secured an LBA for Ph3 data in 2L+ CLDN18.2-positive gastric/GEJ adenocarcinoma alongside the higher-profile IBI363 update. Other notable abstracts include Akeso's AK112 in 1L biliary